research paper presentation
DESCRIPTION
rRole of clathromycin in preventing bronchopulmonary displasia in preterm infanTRANSCRIPT
![Page 1: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/1.jpg)
1
Clarithromycin in preventing Bronchopulmonary
Dysplasia(BPD) in Ureaplasma Urealyticum(Culture positive)
preterm infants
Presented By:Dr. Shergul Solangi
DCH TraineeLGH/PGMI
![Page 2: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/2.jpg)
2
Contents
BPD Ureaplasma Urealyticum Clarithromycin Research Paper introduction
SurveyResults
Conclusion
![Page 3: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/3.jpg)
3
BPD
BPD stands for Broncho Pulmonary Dysplasia
DefinitionSerious and chronic lung disease of newborn
marked by chronic inflammation of airways Causes
PretermRDS (Respiratory distress Syndrome)Oxygen ToxicityMechanical Lung Trauma Infection
![Page 4: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/4.jpg)
4
Continued…
MechanismLungs of babies with BPD are immature or have not
developed normally, therefore, lungs are unable to perform the exchange or incomplete exchange of gases occur.
OccurrenceBPD developed mostly during first 4 weeks of life.90% of infants who developed BPD are premature
and having weight less than 1500gmMale>FemaleNon African increased ratioGenetic factor plays role
![Page 5: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/5.jpg)
5
Continued…
Signs /Symptoms Tachypenia Subcostal recession Wheezing
Diagnosis History Need of oxygen after 28 days Persistence of sign and symptoms X-Ray chest
Note: Most important criteria for diagnosis is need of oxygen even after 28 days
![Page 6: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/6.jpg)
6
Continued…
TreatmentNote: no specific treatment of BPDOxygen supplementationSurfactant administrationMechanical ventilation I/V fluidsBronchodilatorCorticosteroids I/V antibioticsPhysical therapy
![Page 7: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/7.jpg)
7
BPD X-RAY
![Page 8: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/8.jpg)
8
Ureaplasma Urealyticum
IntroductionIt is a gram negative Ds DNA bacteriaFound in urogenital tractIt is normal commensally flora in
reproductive tract especially in womenTransmission is mostly verticalvertical transmissin in full term is 18 to
55% vertical transmission in preterm is 29to
60%
![Page 9: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/9.jpg)
9
Clarithromycin
Macrolides It prevents protein synthesis of bacteria It is more effective than erythromycin Note: it’s concentration is 10 times more in tissues than plasma
especially in liver and lungs Uses
Pharygitis Tonsilitisitis Sinusitis chronic bronchitis Pneumonia
Side effects Jaundice Renal failure Ototoxity Risk of oral candidiasis
![Page 10: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/10.jpg)
10
Research Paper (AAP)
Brief introduction Published on: November 28,2011(Online this December) Researchers : Ramazan Ozdemir et all. Research place: Zekai Tahir Burak Meternity Teaching
Hospital Ankara, Turkey Total neonate studied 272 (48 excluded due to major
congenital problems, so net total newborn studied were 224) Gestational age 27 to 28 weeks Weight 750 to 1250 gms Method: Nasopharyngeal swabs for 1st 3 post natal days Result of culture obtained in max. 48 hours All culture +ve patients followed up to 36 weeks of post
menstrual age .
![Page 11: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/11.jpg)
11
Role of clathromycin in preventing
bronchopulmonary dysplasia in ureaplasma
urelyticum Culture positive preterm
newborns
![Page 12: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/12.jpg)
12
Patients and methods
Nasopharyngeal swabs for ureaplasma urelyticum culture obtained in the first 3 post natal days having birth weight 750 – 1250 gms and having gestational age 27-28 weeks
Infants with +ve culture assigned into two groups . 1) Treated with clathromycin 2) not treated with clathromycin
![Page 13: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/13.jpg)
13
Assessed for enrollment(N=272)
![Page 14: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/14.jpg)
14
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
![Page 15: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/15.jpg)
15
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
![Page 16: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/16.jpg)
16
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
![Page 17: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/17.jpg)
17
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
Clathromycin treatment not given (n= 37)
![Page 18: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/18.jpg)
18
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
Clathromycin treatment not given (n= 37)
Discontinued interventionDeath: spsis (1),
Necrotizig enterocolitis (1)
![Page 19: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/19.jpg)
19
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
Clathromycin treatment not given (n= 37)
Discontinued interventionDeath: spsis (1),
Necrotizig enterocolitis (1)
Discontinued interventionDeath: spsis (3),
Necrotizig enterocolitis (1)
![Page 20: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/20.jpg)
20
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
Clathromycin treatment not given (n= 37)
Discontinued interventionDeath: spsis (1),
Necrotizig enterocolitis (1)
Discontinued interventionDeath: spsis (3),
Necrotizig enterocolitis (1)
Analyzed: 35
![Page 21: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/21.jpg)
21
Assessed for enrollment(N=272)
Excluded (n=48)-Major congenital abnormalties (n=7)-Refused to participate (n=21)-Death (n=12)-Intrauterine growth retardation (n=8)
Randomly assignedCulture –positive (n=74)
Culture-negative (n=150)-Death (n=12)
Clathromycin treatment given
(n= 37)
Clathromycin treatment not given (n= 37)
Discontinued interventionDeath: spsis (1),
Necrotizig enterocolitis (1)
Discontinued interventionDeath: spsis (3),
Necrotizig enterocolitis (1)
Analyzed: 35 Analyzed: 33
![Page 22: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/22.jpg)
22
Treatment given
When positive culture obtained after 48 hrs .Clathromycin treatment started for 10 days
10 mg per kg IV BD for 10 days.
Clathromycin treatment results in eradication of ureaplasma urealticum in 68.5%.
![Page 23: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/23.jpg)
23
Characteristics and out comes of ureaplasma
urealyticum positive patients treted with clathromycin or NOT.
UREAPLASMA UREALYTICUM POSITIVE TREATED WITH CLATHROMYCIN
Birth weight 988 gmsGestational 27 wksMale
13(37)C-section 22(35)Prenatal steriods 24(35)Prom p0sitive 7(35)Chorioamniotis 1(35)
Sepsis
16(35)Pneumonia 3(35)PDA 10(35)Rds 20(35)Poractant RX 11(35)Caffeine RX 26(35)Diuretic Rx 3(35)Duration of M.VENT; 1.8 (4.7)Duration of CPAP 3.7 (3.6)BPD at 36 wks 01(35 )
UREAPLASMA UREALYTICUM POSITIVE NOT TREATED WITH CLATHROMYCIN
Birth weight 978gmsGestational age 27 wksMale 17(33) C-section 19(33)Prenational steriods 20(330Prom POSITIVE 3(33)Chorioamnotis 0(33)Sepsis 14(33)Pneumonia 3(33)PDA 15(33)RDS 21(33)Poractant@ RX 13(33)Caffeine rx 28(33)Diuretic rx 1(33)Duration of M.vent 3.1(4.6)Duration of CPAP 5.8(6.2)BPD at 36 wks 12(33)
![Page 24: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/24.jpg)
24
RESULTS
The rate of BPD development was significantly higher in patients with u.urealyticum culture positive patients that’s 36% as compared to those who are u .urealyticum neg;culture that’s 15% The incidence of BPD is significantly lower in clathromycin treated patients that’s 2.9% as compared to non treated that’s 36%.
![Page 25: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/25.jpg)
25
conclusion
Clathromycin treatment prevents developments of BPD,in preterms who are born at 750 to 1250 gms,colonized with ureaplasma urealyticum and only 01 case of BPD noted ( out of 35 culture positive cases) who are treated with clathromycin,while 12 cases of BPD noted (out of 33 culture poitive patient) who are not treaed with clathromycin.
![Page 26: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/26.jpg)
26
Continued;
Though this study markedly reduces the occurrence of BPD who are ureaplasma urea lyticum positive pts,treated with claththromycin ,but not gives strong association,of ureaplasma urealyticum to develop BPD.
![Page 27: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/27.jpg)
27
SUMMARY
T0tal studied 224
u.urelyticum positive(74) u.urealyticum negative(138)
CLATHROMYCIN(35) NOT RX CLATHRO;(33)
BPD1 (35)-2.9% BPD 12(33) -36.4% 22(138) 15.9%
![Page 28: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/28.jpg)
28
MESSAGE
![Page 29: Research paper presentation](https://reader033.vdocuments.site/reader033/viewer/2022052901/556e07ecd8b42aba5d8b4b03/html5/thumbnails/29.jpg)
29
QUESTIONS 16 -12 -2011